Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Titel:
Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Auteur:
Niemann, Carsten U Munir, Talha Moreno, Carol Owen, Carolyn Follows, George A Benjamini, Ohad Janssens, Ann Levin, Mark-David Robak, Tadeusz Simkovic, Martin Voloshin, Sergey Vorobyev, Vladimir Yagci, Munci Ysebaert, Loic Qi, Keqin Qi, Qianya Sinet, Pierre Parisi, Lori Srinivasan, Srimathi Schuier, Natasha Baeten, Kurt Howes, Angela Caces, Donne Bennett Kater, Arnon P